custom said:
If anyone cares, and I'm sure some do, I will have 17a-4OHN in a liquid solution, which is being done by Black Star Labs, in stock in 2-3 weeks. I will also have 20mg caps of 17a-5aa and Tiratricol caps at 2mg in the same time period. I already have M1T at 10mg caps, really cheap, along with usnic acid and some other goodies. The site should be up in like 2 days. Hopefully Chemo and I can work out some agreement to posting/advertising banner in here....
From PDRhealth.com:
Tiratricol (TRIAC)
DESCRIPTION
Tiratricol is an orphan drug for use in combination with levothyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levothyroxine alone. Tiratricol is a metabolite of the thyroid hormone triiodothyronine (T3) and has thyroid hormone activity.
Tiratricol is also marketed as a dietary supplement for weight-loss purposes. In November, 1999, the Food and Drug Administration (FDA) warned against consuming products containing tiratricol. This was based on reports of individuals using tiratricol developing side effects, such as fatigue, lethargy, profound weight loss and severe diarrhea. They were also found to have abnormal thyroid function tests. Further action by the FDA is being considered.
Tiratricol is also known as triiododothyroacetic acid, TRIAC, 3,5,3' -triiodothyroacetic acid and [4-(4-hydroxy-3-iodophenoxy)-3,5-di-iodophenyl]acetic acid. Its molecular formula is C14H9I3O4, and its molecular weight is 621.9 daltons.
ACTIONS AND PHARMACOLOGY
ACTIONS
Tiratricol has thyroid hormone activity, including various metabolic effects. It also inhibits the secretion of thyroid-stimulating hormone (TSH) by the pituitary gland.
MECHANISM OF ACTION
The mechanism by which thyroid hormones exert their various actions has not been completely elucidated. Tiratricol is known to act as a feedback inhibitor of TSH secretion by the pituitary gland.
PHARMACOKINETICS
Much is unknown about the pharmacokinetics of tiratricol in humans. The pharmacokinetics of tiratricol appear to be similar to those of thyroxine and triiodothyronine. Tiratricol is absorbed from the small intestine following ingestion. Distribution of tiratricol in the body has not been fully elucidated. Most of this substance appears to be bound to serum proteins, including thyroxine-binding protein and albumin. It appears to be less firmly bound to serum proteins than are T4 and T3. The liver appears to be the major site of degradation of tiratricol. Tiratricol appears to be conjugated with glucuronic acid and sulfuric acid and excreted in the bile. Mainly because it is less tightly bound to serum proteins, tiratricol has a shorter half-life than T4 or T3.
INDICATIONS AND USAGE
The FDA has warned consumers not to purchase tiratricol-containing products due to risk of serious health consequences, including heart attacks and strokes. Tiratricol should be used only under a physician's supervision. Tiratricol is currently used by some as a supplement to burn fat. The doses required to achieve this effect pose significant health risks.
RESEARCH SUMMARY
Tiratricol is an orphan drug. The FDA has determined that it should not be used as a nutritional supplement due to serious potential health risks including heart attack and stroke.
CONTRAINDICATIONS, PRECAUTIONS, ADVERSE REACTIONS
CONTRAINDICATIONS
Tiratricol is contraindicated in those with untreated thyrotoxicosis of any etiology and in those with uncorrected adrenal insufficiency. Thyroid hormones increase tissue demands for adrenocortical hormones and may thereby precipitate acute adrenal crisis. Tiratricol is also contraindicated in those who are hypersensitive to any component of a tiratricol-containing product.
PRECAUTIONS
Tiratricol should only be used for specific approved indications and only under strict medical supervision. Tiratricol should not be used as a treatment for obesity. Tiratricol should be used with extreme caution in those with cardiovascular disorders (including angina, coronary artery disease and hypertension) and in the elderly who have a greater likelihood of occult cardiac disease. Concomitant use of tiratricol and sympathomimetic agents in those with coronary artery disease may increase the risk of coronary insufficiency.
Use of tiratricol in those with concomitant diabetes mellitus, diabetes insipidus or adrenal cortical insufficiency may aggravate the intensity of their symptoms.
ADVERSE REACTIONS
Reported adverse reactions include fatigue, lethargy, profound weight loss and severe diarrhea. Tiratricol has also been reported to cause abnormal thyroid function tests.
INTERACTIONS
DRUGS
Anticoagulants (oral). The hypoprothrombinemic effect of anticoagulants, such as warfarin, may be potentiated.
Sympathomimetic agents. There is a possible increased risk of coronary insufficiency in those with coronary artery disease.
Thyroid drugs (levothyroxine, triiodothyronine, thyroid). Concomitant use of tiratricol with these thyroid drugs is likely to produce additive effects.
LABORATORY TESTS
Tiratricol is likely to alter thyroid function tests, including TSH, T4 and T3.
OVERDOSAGE
There have been no reports of overdosage with tiratricol. Excessive doses of tiratricol theoretically may result in a hypermetabolic state indistinguishable from thyrotoxicosis.
DOSAGE AND ADMINISTRATION
Tiratricol is not recommended for use as a dietary supplement.
LITERATURE
Anon. FDA warns against consuming dietary supplements containing tiratricol. FDA Talk Paper. Nov 21, 2000.
Bracco D, Morin O, Schutz Y, et al. Comparison of the metabolic effects of 3,5,3'-triiodothyroacetic acid and thyroxine. J Clin Endocrin Met. 1993; 77:221-228.
Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid. 1997; 7:775-778.
Takeda T, Suzuki S, Liu RT, DeGroot LJ. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab. 1995; 80:2033-2040.